Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SKL27969 |
Synonyms | |
Therapy Description |
SKL27969 inhibits PRMT5, potentially resulting in decreased cell proliferation and inhibition of tumor growth (Neuro Oncol 24, Supplement 7 (November 2022) vii233-vii234). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SKL27969 | SKL 27969|SKL-27969 | PRMT5 Inhibitor 17 | SKL27969 inhibits PRMT5, potentially resulting in decreased cell proliferation and inhibition of tumor growth (Neuro Oncol 24, Supplement 7 (November 2022) vii233-vii234). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Terminated | USA | 0 |